Mohd Mustafa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohd Mustafa has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kashif Abbas
Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202001, India
2 shared publications - Mudassir Alam
Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India
2 shared publications - Farha Fatima
Department of Zoology Former PhD Graduate Aligarh Muslim University Aligarh India
1 shared publication - Khalid Alhazmi
Department of Pathology University of Tabuk Tabuk Saudi Arabia
1 shared publication - Mohammad Zubair
Department of Medical Microbiology, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi Arabia
1 shared publication - Muhammad Ahmed Mesaik
Department of Medical Microbiology, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi Arabia
1 shared publication
Latest Publications
- 28 October 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (41)
Antimicrobial and Antibiofilm Activity of Biogenic MgO Nanoparticles and Extract from Hibiscus sabdariffa Against Multidrug Resistance
Diabetic foot ulcers (DFUs) often involve multidrug‐resistant (MDR) infections, complicating treatment. Plant extracts and green‐synthesized nanoparticles are promising alternatives for combating these pathogens. This study aimed to evaluate the antimicrobial and antibiofilm effects of Hibiscus sabdariffa extracts and magnesium oxide nanoparticles (MgO‐GNPs) against MDR bacteria isolated from DFUs, while exploring their mechanisms through in silico analysis. Qualitative phytochemical analysis was performed on Hibiscus extracts. The MgO‐NPs were characterized using Fourier transform infrared spectroscopy (FTIR), X‐ray diffraction (XRD), ultraviolet–visible spectroscopy (UV–vis), energy dispersive X‐ray analysis (EDX), and scanning electron microscope (SEM). Their antimicrobial effects by MIC against E. coli , P. aeruginosa , and S. aureus . Biofilm inhibition and disruption were assessed in mono‐ and mixed‐species cultures. Molecular docking and molecular dynamics simulations explored interactions between MgO‐GNPs and bacterial enzymes. MgO‐GNPs demonstrated superior antimicrobial activity, with MICs between 22 and 36 µg/mL. They significantly inhibited biofilm formation and disrupted existing biofilms more effectively than Hibiscus extracts. MgO‐GNPs increased ROS levels, damaged bacterial membranes, and suppressed exopolysaccharide and alginate production. In silico studies showed strong binding affinity of MgO‐GNPs to bacterial glycosyltransferases, supporting their mechanism of action. MgO‐GNPs show promising antimicrobial and antibiofilm activity against MDR pathogens. Their ability to target biofilms and bacterial mechanisms suggests they could serve as effective alternatives for managing drug‐resistant DFU infections.
- 28 October 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (41)
Antimicrobial and Antibiofilm Activity of Biogenic MgO Nanoparticles and Extract from Hibiscus sabdariffa Against Multidrug Resistance
Diabetic foot ulcers (DFUs) often involve multidrug‐resistant (MDR) infections, complicating treatment. Plant extracts and green‐synthesized nanoparticles are promising alternatives for combating these pathogens. This study aimed to evaluate the antimicrobial and antibiofilm effects of Hibiscus sabdariffa extracts and magnesium oxide nanoparticles (MgO‐GNPs) against MDR bacteria isolated from DFUs, while exploring their mechanisms through in silico analysis. Qualitative phytochemical analysis was performed on Hibiscus extracts. The MgO‐NPs were characterized using Fourier transform infrared spectroscopy (FTIR), X‐ray diffraction (XRD), ultraviolet–visible spectroscopy (UV–vis), energy dispersive X‐ray analysis (EDX), and scanning electron microscope (SEM). Their antimicrobial effects by MIC against E. coli , P. aeruginosa , and S. aureus . Biofilm inhibition and disruption were assessed in mono‐ and mixed‐species cultures. Molecular docking and molecular dynamics simulations explored interactions between MgO‐GNPs and bacterial enzymes. MgO‐GNPs demonstrated superior antimicrobial activity, with MICs between 22 and 36 µg/mL. They significantly inhibited biofilm formation and disrupted existing biofilms more effectively than Hibiscus extracts. MgO‐GNPs increased ROS levels, damaged bacterial membranes, and suppressed exopolysaccharide and alginate production. In silico studies showed strong binding affinity of MgO‐GNPs to bacterial glycosyltransferases, supporting their mechanism of action. MgO‐GNPs show promising antimicrobial and antibiofilm activity against MDR pathogens. Their ability to target biofilms and bacterial mechanisms suggests they could serve as effective alternatives for managing drug‐resistant DFU infections.
- 10 October 2025
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 22, 1-25
Management of Major Depressive Disorder by Citalopram: A Double-edged Sword
Major depressive disorder (MDD) affects over 280 million people globally, presenting a significant public health challenge. This review evaluates the use of citalopram, a selective serotonin reuptake inhibitor (SSRI), in MDD management, focusing on its therapeutic efficacy and the critical adverse effect of citalopram-induced hyponatremia (CIH). Through a comprehensive literature analysis, we explore the medicinal chemistry of citalopram, its mode of action, and the mechanisms underlying CIH, primarily associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Findings indicate that CIH affects 9-40% of patients, with a higher prevalence in vulnerable populations such as the elderly and cancer patients, where it complicates treatment due to interactions with disease-related factors. Routine serum sodium monitoring is recommended for individuals at risk to mitigate potential risks. The review highlights the need for tailored treatment strategies to balance citalopram’s benefits against CIH risks, particularly in cancer patients, and identifies future research directions for personalized MDD management.
- 10 October 2025
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 22, 1-25
Management of Major Depressive Disorder by Citalopram: A Double-edged Sword
Major depressive disorder (MDD) affects over 280 million people globally, presenting a significant public health challenge. This review evaluates the use of citalopram, a selective serotonin reuptake inhibitor (SSRI), in MDD management, focusing on its therapeutic efficacy and the critical adverse effect of citalopram-induced hyponatremia (CIH). Through a comprehensive literature analysis, we explore the medicinal chemistry of citalopram, its mode of action, and the mechanisms underlying CIH, primarily associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Findings indicate that CIH affects 9-40% of patients, with a higher prevalence in vulnerable populations such as the elderly and cancer patients, where it complicates treatment due to interactions with disease-related factors. Routine serum sodium monitoring is recommended for individuals at risk to mitigate potential risks. The review highlights the need for tailored treatment strategies to balance citalopram’s benefits against CIH risks, particularly in cancer patients, and identifies future research directions for personalized MDD management.